Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumati Gupta

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
BJU International|April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaborationPraful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Journal for Immunotherapy of Cancer|September 17, 2025
Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escapeBing-Jian Feng, Wendy Kohlmann, David A Nix, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2021
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021Efrat Dotan, Louise C Walter, Ilene S Browner, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
BJU International|April 28, 2021
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaborationPraful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, et al.
Journal for Immunotherapy of Cancer|November 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumorsKevin Conlon, Dionysios C Watson, Thomas A Waldmann, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Journal for Immunotherapy of Cancer|September 17, 2025
Germline whole-exome sequencing reveals <i>FOXP3</i>-related gene variants conferring urinary cancer susceptibility and associated with immune escapeBing-Jian Feng, Wendy Kohlmann, David A Nix, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2021
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021Efrat Dotan, Louise C Walter, Ilene S Browner, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Pageof 7